Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics

Alnylam Pharmaceuticals (ALNY) reported $494.33 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 54.8%. EPS of -$0.16 for the same period compares to -$1.40 a year ago.

The reported revenue represents a surprise of +17.39% over the Zacks Consensus Estimate of $421.1 million. With the consensus EPS estimate being -$0.75, the EPS surprise was +78.67%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Product revenues, net: $365.16 million versus the eight-analyst average estimate of $344 million. The reported number represents a year-over-year change of +32.2%.
  • Royalty revenue: $10.62 million versus $18.66 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +63.4% change.
  • Net revenues from research collaborators: $118.55 million versus $58.26 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +225.1% change.
  • Net Product Revenue- Oxlumo: $42.65 million compared to the $32.68 million average estimate based on six analysts. The reported number represents a change of +76.5% year over year.
  • Net Product Revenues- Givlaari: $58.06 million versus $60.32 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +21.2% change.
  • Net Product Revenues- Onpattro: $69.22 million compared to the $63.24 million average estimate based on five analysts. The reported number represents a change of -32.5% year over year.
  • Net Product Revenue- Amvuttra: $195.24 million versus the five-analyst average estimate of $183.80 million.
View all Key Company Metrics for Alnylam here>>>

Shares of Alnylam have returned -0.6% over the past month versus the Zacks S&P 500 composite's -4.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.2% per year. So be sure to give these hand picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.